RT Conference Proceedings
T1 Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%
A1 Spira, A.
A1 Planchard, D.
A1 Cho, B. C.
A1 Ozguroglu, M.
A1 Daniel, D.
A1 Villegas, A.
A1 Vicente, D.
A1 Hui, R.
A1 Murakami, S.
A1 Paz-Ares, L.
A1 Boothman, A.
A1 Poole, L.
A1 Wadsworth, C.
A1 Dennis, P.
A1 Antonia, S.
K1 durvalumab
K1 PACIFIC
K1 PD-L1
PB Elsevier science inc
SN 1556-0864
YR 2018
FD 2018-10-01
LK https://hdl.handle.net/10668/27563
UL https://hdl.handle.net/10668/27563
LA en
DS RISalud
RD Apr 17, 2025